{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:15:03Z","timestamp":1790374503983,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007380","name":"Funda\u00e7\u00e3o Instituto de Pesquisas Econ\u00f4micas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["0730\/2020"],"award-info":[{"award-number":["0730\/2020"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","award":["2020\/0731"],"award-info":[{"award-number":["2020\/0731"]}],"id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014772","name":"Colorado Department of Transportation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Jornal de Pediatria"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jped.2024.07.011","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:40:11Z","timestamp":1729100411000},"page":"38-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2978-500X","authenticated-orcid":false,"given":"Ana Let\u00edcia Amorim","family":"de Albuquerque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2362-9202","authenticated-orcid":false,"given":"J\u00falia Kersting","family":"Chadanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2008-2336","authenticated-orcid":false,"given":"Isabela Possebon","family":"Bevilacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-1056","authenticated-orcid":false,"given":"Ana Lucia Portella","family":"Staub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1952-9222","authenticated-orcid":false,"given":"Pablo Brea","family":"Winckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-8997","authenticated-orcid":false,"given":"Patricia Zambone","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-2488","authenticated-orcid":false,"given":"Simone Chaves","family":"Fagondes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8992-2607","authenticated-orcid":false,"given":"Renata Salatti","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0729-0254","authenticated-orcid":false,"given":"Claudia Denise de Oliveira","family":"Trojahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0030-6762","authenticated-orcid":false,"given":"Viviane Zechlinski","family":"Sacharuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5799-2272","authenticated-orcid":false,"given":"Thayne Woycinck","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3028-3163","authenticated-orcid":false,"given":"Karina Carvalho","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1232-5896","authenticated-orcid":false,"given":"Michele Michelin","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1141-6573","authenticated-orcid":false,"given":"Jonas Alex Morales","family":"Saute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jped.2024.07.011_bib0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jped.2024.07.011_bib0002","first-page":"1","article-title":"Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy","volume":"82","author":"Zanoteli","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jped.2024.07.011_bib0003","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jped.2024.07.011_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jped.2024.07.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2023-0126","article-title":"Neonatal screening for spinal muscular atrophy: a pilot study in Brazil","volume":"46","author":"Oliveira Netto","year":"2023","journal-title":"Genet Mol Biol"},{"key":"10.1016\/j.jped.2024.07.011_bib0006","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-4939-8651-4_4","article-title":"Nusinersen in the treatment of spinal muscular atrophy","volume":"1828","author":"Goodkey","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jped.2024.07.011_bib0007","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jped.2024.07.011_bib0008","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs."},{"key":"10.1016\/j.jped.2024.07.011_bib0009","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas: Atrofia Muscular Espinhal 5q Tipo 1. Brasil: Minist\u00e9rio da Sa\u00fade","year":"2019"},{"key":"10.1016\/j.jped.2024.07.011_bib0010","series-title":"Portaria Conjunta n.o 6, De 15 De Maio De 2023. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas \u2013 Atrofia Muscular Espinhal 5q Tipos 1 e 2. Brasil: Minist\u00e9rio da Sa\u00fade","year":"2022"},{"key":"10.1016\/j.jped.2024.07.011_bib0011","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas: Atrofia Muscular Espinhal (AME) 5q Tipos I e II","year":"2023"},{"key":"10.1016\/j.jped.2024.07.011_bib0012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JND-200551","article-title":"Real-world data from nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience","volume":"8","author":"Mendon\u00e7a","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.jped.2024.07.011_bib0013","series-title":"Minist\u00e9rio Da Sa\u00fade","year":"2022"},{"key":"10.1016\/j.jped.2024.07.011_bib0014","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1055\/s-0043-1772832","article-title":"Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation","volume":"81","author":"Alves","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jped.2024.07.011_bib0015","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jped.2024.07.011_bib0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jped.2024.07.011_bib0017","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1590\/0004-282x20190073","article-title":"Observations from a nationwide vigilance program in medical care for spinal muscular atrophy patients in Chile","volume":"77","author":"Alvarez","year":"2019","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jped.2024.07.011_bib0018","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","article-title":"Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States","volume":"12","author":"Lally","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jped.2024.07.011_bib0019","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1212\/NXG.0000000000000505","article-title":"E. Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy","volume":"6","author":"Mendon\u00e7a","year":"2020","journal-title":"Neurol Genet"},{"key":"10.1016\/j.jped.2024.07.011_bib0020","first-page":"35","article-title":"Physical therapy services received by individuals with spinal muscular atrophy (SMA)","volume":"9","author":"Dunaway","year":"2016","journal-title":"J Pediatr Rehabil Med"},{"key":"10.1016\/j.jped.2024.07.011_bib0021","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jped.2024.07.011_bib0022","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jped.2024.07.011_bib0023","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1017\/cjn.2021.231","article-title":"Ontario Newborn Screening for Spinal Muscular Atrophy: the First Year","volume":"49","author":"Kernohan","year":"2022","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jped.2024.07.011_bib0024","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jped.2024.07.011_bib0025","series-title":"Atrofia Muscular Espinhal (AME) 5q Tipos I e II. Brasil: Minist\u00e9rio da Sa\u00fade","year":"2022"},{"key":"10.1016\/j.jped.2024.07.011_bib0026","unstructured":"Sociedades Brasileiras de Neurologia Infantil e de Gen\u00e9tica M\u00e9dica. Nota das Sociedades Brasileiras de Neurologia Infantil e de Gen\u00e9tica M\u00e9dica sobre uso de Nusinersena no cen\u00e1rio brasileiro para pacientes com Atrofia Muscular Espinhal 5q. 2018 [Accessed July 1, 2024. Available from:https:\/\/sbni.org.br\/wp-content\/uploads\/2018\/09\/Nota-do-Grupo-de-trabalho-AME-SBNI-e-SBGM-1.pdf"},{"key":"10.1016\/j.jped.2024.07.011_bib0027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1590\/0004-282x-anp-2020-0200","article-title":"Managing intrathecal administration of nusinersen in adolescents and adults with 5q-spinal muscular atrophy and previous spinal surgery","volume":"79","author":"Mendon\u00e7a","year":"2021","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jped.2024.07.011_bib0028","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1590\/0103-11042019s418","article-title":"O tratamento de doen\u00e7as raras no Brasil: a judicializa\u00e7\u00e3o e o Complexo Econ\u00f4mico-Industrial da Sa\u00fade","volume":"43","author":"D'Ippolito","year":"2020","journal-title":"Sa\u00fade Debate"}],"container-title":["Jornal de Pediatria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021755724001268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021755724001268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:47:40Z","timestamp":1777409260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021755724001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0021755724001268"],"URL":"https:\/\/doi.org\/10.1016\/j.jped.2024.07.011","relation":{},"ISSN":["0021-7557"],"issn-type":[{"value":"0021-7557","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil","name":"articletitle","label":"Article Title"},{"value":"Jornal de Pediatria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jped.2024.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}